Starling Oncology, Inc. (STLN) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Starling Oncology, Inc. (STLN) Earnings Overview
As of November 18, 2026, Starling Oncology, Inc. (STLN) reported trailing twelve-month net income of -$36M. The company earned $-0.03 per diluted share over the past four quarters, with a net profit margin of -12.1%.
Looking at the long-term picture, STLN's historical earnings data spans multiple years. The company achieved its highest annual net income of $152,000 in fiscal 2022.
Starling Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AIOT (-$21M net income, -4.6% margin), ONCO (-$33M net income, -1721.0% margin), USPH (-$2M net income, 1.9% margin), STLN has room to improve margins relative to the peer group. Compare STLN vs AIOT →
STLN Earnings vs Peers
Earnings metrics vs comparable public companies
STLN Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$61M | +6.3% | -$36M | $-0.54 | -12.1% | -7.2% |
| 2024 | -$65M | +22.2% | -$60M | $-0.71 | -16.4% | -15.3% |
| 2023 | -$83M | -54750.0% | -$77M | $-0.92 | -25.6% | -23.8% |
| 2022 | $152,000 | +101.4% | -$82M | $-0.21 | 0.1% | -32.5% |
| 2021 | -$11M | +23.7% | -$46M | $-0.16 | -5.4% | -22.6% |
| 2020 | -$14M | -256.1% | -$8M | $-0.24 | -7.6% | -4.4% |
| 2019 | -$4M | - | -$3M | $-0.06 | -2.6% | -1.7% |
Download Data
Export STLN earnings history in CSV or JSON format
Free sign-in required to download data
STLN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
STLN — Frequently Asked Questions
Quick answers to the most common questions about buying STLN stock.
What is STLN earnings per share (EPS)?
STLN trailing twelve-month (TTM) diluted EPS is $-0.03, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Starling Oncology, Inc.'s net income?
Starling Oncology, Inc. (STLN) trailing twelve-month net income is $-36M as of 2025. Earnings declined N/A year-over-year.
Is STLN profitable?
STLN is not currently profitable on a TTM basis, reporting a net loss of $-36M. Net margin is -12.1%. Investors should monitor for a return to profitability.
What is STLN's earnings growth rate?
STLN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are STLN's profit margins?
Starling Oncology, Inc. net profit margin is -12.1%, operating margin is -7.2%, and gross margin is +15.2%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is STLN growing earnings?
STLN TTM EPS: $-0.03. Net income: $-36M. YoY earnings change: N/A.
What was STLN's best earnings year?
Starling Oncology, Inc.'s highest annual net income on record is $152000.00, achieved in fiscal year 2022. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were STLN's earnings last quarter?
STLN's most recent reported quarter was Q3 2026. Net income was $-16M with diluted EPS of $-0.13. For a full breakdown of all quarters, see the quarterly earnings table on this page.